BRCA1 and ovarian cancer: In a study of BRCA1-deficient ovarian cancer, dendritic cells expressed upregulated levels of CD80, CD86, and MHC II expression after olaparib treatment in comparison to the study’s vehicle control and the PD-1 antibody [170].